| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Lirilumab | IPH-21; NN-1975; IPH-2101; IPH-2102; BMS-986015 | Phase 2 Clinical | Novo Nordisk A/S | Leukemia; Bone Marrow Neoplasms; Squamous Cell Carcinoma of Head and Neck; Leukemia, Lymphoid; Hodgkin Disease; Neoplasms; Smoldering Multiple Myeloma; Multiple Myeloma; Urinary Bladder Neoplasms; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Biphenotypic, Acute | Details |